Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: A systematic review

Rheumatology International

Volumn 26, Issue 6, 2006, Pages 481-488

  Tinazzi, Elisa ^a   Ficarra, Vincenzo ^a   Simeoni, Sara ^a   Artibani, Walter ^a   Lunardi, Claudio ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b Clinica di Medicina Interna D   (Italy)

Author keywords

BCG immunotherapy; Cytokines; Molecular mimicry; Reactive arthritis

Indexed keywords

BCG VACCINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FREQUENCY ANALYSIS; GENETIC PREDISPOSITION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; PATHOGENESIS; PRIORITY JOURNAL; RARE DISEASE; REACTIVE ARTHRITIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ARTHRITIS, REACTIVE; BCG VACCINE; CARCINOMA; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MODELS, IMMUNOLOGICAL; MOLECULAR MIMICRY; URINARY BLADDER NEOPLASMS;

EID: 33645358368     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-005-0059-2     Document Type: Review

References (90)

1. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics 2004. Cancer J Clin 54:8-29
2. Messing EM, Catalona W (1998) Urothelial tumors of the urinary tract. Campbell's urology, 7th edn. WB Saunders Co, Philadelphia
3. Dalbaghi G, Herr HW (2000) Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 27:137-146
4. Herr HW (2000) Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year out-come. J Urol 163:60-62
5. Herr HW, Schwalb DM, Zhang ZF et al (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13:1404-1416
6. Nseyo UO, Lamm DL (1996) Therapy of the superficial bladder cancer. Semin Oncol 23:598-604
7. Cheng CW, Chan SFP, Chan LW, Chan CK, Ng CF, Cheung HY et al (2004) 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach. Jpn J Clin Oncol 34 (4):202-205
8. Morales A, Nickel JG (1976) Immunotherapy of superficial bladder cancer with BCG. World J Urol 3:209-214
9. Lamm DL (2000) Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 31 (Suppl 3):S86-S90
10. Talic RF, Hargreave TB, Bishop MC, Kirk D, Prescott S (1994) Intravesical Evans bacille Calmette-Guerin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group. Br J Urol 73:645-648
11. Morales A, Ottenhof P, Emerson L (1981) Treatment of residual non infiltrating bladder cancer with Bacillus Calmette-Guerin. J Urol 125:649-651
12. Lamm DL, Blumenstein BA, Crawford ED et al (1991) A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med 325:1205-1209
13. Hurle R, Losa A, Manzetti A, Lembo A (1999) Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7 year follow-up. Urology 54:258-263
14. Herr HW, Pinsky CM, Whitemore WF, Sogani PC, Oettgen HF, Melamed MR (1986) Long term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol 135:265-267
15. Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296-1299
16. Satoh A, Hanawa Y, Nakamura S (2004) Clinical study of bladder cancer: proteinuria as a predictor of recurrence and efficacy of intravesical bacille Calmette-Guerin therapy. Int J Urol 11:476-482
17. Lamm DL, Van der Meijden ADPM, Morales A et al (1992) Incidence and treatment of Bacillus Calmette Guerain intravesical therapy in superficial bladder cancer. J Urol 147:596-600
18. Tinazzi E, Ficarra V, Simeoni S, Peterlana D, Lunardi C (2005) Reactive arthritis following BCG immunotherapy for bladder cancer. Clin Rheumatol 24:425-427
19. Lamm DL, Stodgill VD, Stodgill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer. J Urol 135:272-274
20. Hughes RA, Allard SA, Maini RN (1989) Arthritis associated with adjuvant mycobacterial treatment for carcinoma of the bladder. Ann Rheum Dis 48:432-434
21. Ochsenkuhn T, Weber MM, Caselmann WH (1990) Arthritis after Mycobacterium bovis immunotherapy for bladder cancer. Ann Int Med 112:882
22. al Khalifa MA, Elfving P, Mansson W, Colleen S (1991) Bacillus Calmette-Guerin treatment of 39 patients with superficial transitional cell carcinoma of the bladder. Scand J Urol Nephrol 25:135-139
23. Kudo S, Tsushima N, Sawadaa Y, Saito F, Motomura F, Takashima T, Kogawa T, Suzuki T, Kurotaki H, Masumori J et al (1991) Serious complications of intravesical bacillus Calmette-Guerin therapy in patients with bladder cancer. Nippon Hinyokika Gakkai Zosshi 82:1594-1602
24. Chapman PT, Mark SD, Moller PW (1992) Arthritis associated with adjuvant mycobacterial treatment for carcinoma of the bladder. N Z Med J 105:37-38
25. Van Thiel RJ, Nossent GD, Tjon Pian Gi NP (1992) Articular complications of intravesical BCG treatment for bladder carcinoma. Br J Urol 70:446-447
26. Goupille P, Soutif D, Valat JP (1992) Arthritis after Calmette-Guerin bacillus immunotherapy for bladder cancer. J Rheumatol 19:1825-1826
27. Chazerain P, Desplaces N, Ziza JM, Pierrot S, Cordonnier C, Chanzy M (1992) BCG osteoarthritis on knee prosthesis after intra-vesical BCG therapy. Rev Rhum Mal Osteoartic 59:836-838
28. Belmatoug N, Levy-Djebbour S, Appelboom T et al (1993) Polyarthritis in 4 patients treated with intravesical BCG-therapy for carcinoma of the bladder. Rev Rhum Ed Fr 60:162-166
29. Faus S, Martinez Montauti JM, Puig L (1993) Reiter's syndrome after administration of intravesical bacille Calmette-Guerin. Clin Infect Dis 17:526-527
30. Xerri B, Chretien Y, Le Parc JM (1993) Reactive polyarthritis induced by intravesical BCG therapy for carcinoma of the bladder. Eur J Med 2:503-505
31. Jawad AS, Kahan L, Copland RF, Henderson DC, Abdul-Ahad AK (1993) Reactive arthritis associated with bacillus Calmette-Guerin immunotherapy for carcinoma of the bladder: a report of two cases. Br J Rheumatol 32:1018-1020
32. Pancaldi P, Van Linthoudt D, Alberino D, Haefliger JMM, Ott H (1993) Reiter's syndrome after intravesical bacillus Calmette-Guerin treatment for superficial bladder carcinoma. Br J Rheumatol 32:1096-1098
33. Price GE (1994) Arthritis and iritis after BCG therapy for bladder cancer. J Rheumatol 21:564-565
34. Goupille P, Poet JL, Jattiot F, Mattei JP, Vedere V, Tonolli-Serabian J et al (1994) Three cases of arthritis after BCG therapy for bladder cancer. Clin Exp Rheumatol 12:195-197
35. Varoqua S, Lin-Greenberg A, Brown M (1994) Polyarthritis in an elderly man with bladder cancer. Hosp Pract 29:75-78
36. Devlin M, Deodhar A, Davis M (1994) Arthritis as a complication of intravesical BCG vaccine. Br Med J 308:1638
37. Thepot C, Martigny J, Simon L, Bellin J, Larget-Piet B, Chevalier X (1995) Acute polyarthritis after BCG-therapy for bladder carcinoma in a patient with ankylosing spondylitis. Rev Rhum Engl Ed 62:459-461
38. Queiro R, Ballina J, Weruaga A, Fernandez JA, Rientra JL, Torre JC, Rodriguez A (1995) Psoriatic arthropathy after BCG immunotherapy for bladder cancer. Br J Rheumatol 34:1097
39. Hammadeh MY, Dutta SN, Worraall JG, Morgan RJ (1995) Acute reactive polyarthritis after intravesical bacillus Calmette-Guerin instillation. Br J Urol 76:811-812
40. Goupille P, Valat JP (1996) Arthritis after bacillus Calmette-Guerin therapy. J Rheumatol 23:1481-1482
41. Miossec P (1996) Reactive arthritis associated with bacillus Calmette-Guerin immunotherapy for carcinoma of the bladder: immune reactivity against mycobacterial antigens. J Rheumatol 23:1485
42. Rodevand E, Faxvaag A, Ostensen M, Brevik B (1996) Arthritis after BCG treatment of bladder cancer. A rare complication. Tidsskr Nor Laegeforen 116:3231-3232
43. Smith MD, Chandran G, Parker, Youssef PP, Ahern M, Coleman MA et al (1997) Synovial membrane cytokine profiles in reactive arthritis secondary to intravesical bacillus Calmette-Guerin therapy. J Rheumatol 24:752-758
44. Saporta L, Gumus E, Karadag H, Kuran B, Miroglu C (1997) Reiter syndrome following intracavitary BCG administration. Scand J Urol Nephrol 31:211-212
45. Farahat MN (1997) Selective migration of the human helper/ inducer T-cell subset (CD4+) in BCG-induced arthritis. Biochem Soc Trans 25:3718
46. Hansen CP, Mortensen S (1997) Epididimo-orchitis and Reiter's disease. Two infrequent complications after intravesical bacillus Calmette-Guerin therapy. Scand J Urol Nephrol 31:317-318
47. Gaston JS (1998) Role of T-cells in the development of arthritis. Clin Sci 95:19-31
48. Fond L, Bencharif L, Guglielminotti C, Lauwers A, Lucht F (1998) Acute oligo-arthritis in a patient treated with BCG therapy for bladder carcinoma. Presse Med 27:475
49. Milas L, Maillefert JF, Michel F, Piroth C, Wautot A, Tavernier C (1999) Refractory arthropathy after intravesical bacillus Calmette-Guerin therapy. Usefulness of isoniazide. Rev Rhum Engl Ed 66:106-108
50. Clavel G, Grados F, Cayrolle G, Bellony R, Leduc I, Lafont B, Ducroix JP, Fardellone P (1999) Polyarthritis following intravesical BCG immunotherapy. Report of a case and review of 26 cases in the literature. Rev Rhum Engl Ed 66:115-118
51. Onur O, Celiker R (1999) Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Rheumatol 18:74-76
52. Schwartzenberg JM, Smith DD, Lindsley HB (1999) Bacillus Calmette-Guerin associated arthropathy mimicking undifferentiated spondyloarthropathy. J Rheumatol 26:933-935
53. Chevrel G, Zech C, Miossec P (1999) Severe uveitis followed by reactive arthritis after bacillus Calmette-Guerin therapy. J Rheumatol 26:1011
54. Varentsov GI, Zakhmatov IuM, Kornev AI, Otvetchikov IN (1999) Polyarthritis as a rare complication in BCG immunoprophylaxis of urinary bladder cancer. Urologia 5:29-30
55. Aharon-Maor A, Shoenfeld Y (2000) The good, the bad and the ugly of vaccination. Isr Med Assoc J 2:225-227
56. Hodish I, Ezra D, Gur H, Strego R, Olchovsky D (2000) Reiter's syndrome after intravesical bacillus Calmette-Guerin therapy for bladder cancer. Isr Med Assoc J 2:240-241
57. Hogarth MB, Thomas S, Seifert MH, Tariq SM (2000) Reiter's syndrome following intravesical BCG therapy. Postgrad Med J 76:791-793
58. Mouly S, Berenbaum F, Kaplan G (2001) Remitting seronegative symmetrical synovitis with pitting edema following intravesical bacillus Calmette-Guerin instillation. J Rheumatol 28:1699-1701
59. Shoenfeld Y, Aron-Maor A, Tanai A, Ehrenfeld M (2001) BCG and autoimmunity: another two-edged sword. J Autoimmun 16:235-240
60. Neumayr C, Kirchgatterer A, Knoflach P (2002) Chronic reactive arthritis associated with Calmette-Guerin bacillus. Dtsch Med Wochenschr 127:1886-1888
61. Pardalidis NP, Papatsoris AG, Kosmaoglou EV, Georganas C (2002) Two cases of acute polyarthritis secondary to intravesical BCG adjuvant therapy for superficial bladder cancer. Clin Rheumatol 21:536-537
62. Bartolome Pacheco MJ, Martinez-Taboada VM, Blanco R, Rodriguez-Valverde V, Valle JI, Lopez-Hoyos M (2002) Reactive arthritis after BCG immunotherapy: T cell analysis in peripheral blood and synovial fluid. Rheumatology 41: 1119-1125
63. Mas AJ, Romera M, Valverde-Garcia JM (2002) Articular manifestations after the administration of intravesical BCG. Joint Bone Spine 69:92-93
64. Pego JM, Lamas C, Hernandez I, Suso J (2003) Relapsing Reiter's syndrome after bacillus Calmette-Guerin immunotherapy for bladder carcinoma. Med Clin 121:356-357
65. Shiba M, Fujii T, Takatera H (2003) Reiter syndrome after intravesical bacillus Calmette-Guerin (BCG) immunotherapy: a case report. Hinyokika Kiyo 49:599-601
66. Narvaez J, Castro-Bohorquez FJ, Vilaseca-Momplet J (2003) Sjogren's-like syndrome following intravesical bacillus Calmette-Guerin immunotherapy. Am J Med 115:418-419
67. Lam JS, Benson MC, O'Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH et al (2003) Bacillus Calmette-Guerin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21:354-360
68. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636-1642
69. Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S et al (1995) Changes in urinary cytokines and solubile intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99:369-375
70. Luo Y, Chen X, O'Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-inbuced IFN-γ production: cytokine promotion and stimulation of BCG effect. Cytokine 21:17-26
71. Hara I, Nagai H, Miyake H et al (2000) Effectiveness of cancer vaccine therapy using cells transduced with the interleukine-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 7:83-90
72. Nagai H, Hara I, Horikawa T et al (2000) Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest 18:206-13
73. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L et al (2001) T-helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 166:2142-2147
74. Arnold J, de Boer EC, O'Donnell MA, Bohle A, Brandau S (2004) Immunotherapy of experimental bladder cancer with recombinant BCG expressing Interferon-gamma. J Immunother 27:116-123
75. Yu DS, Lee CF, Hsieh DS, Chang SY (2004) Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Urology 63:596-601
76. Lunardi C, Bason C, Navone R et al (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6:1183-1186
77. Pearson CM (1964) Experimental models in rheumatoid disease. Arthritis Rheum 7:80-86
78. Buchs N, Chevrel G, Miossec P (1998) Bacillus Calmette-Guerin induced aseptic arthritis: an experimental model of reactive arthritis. J Rheumatol 25:1662-1665
79. Dulphy N, Peyrat M-A, Tieng V et al (1999) Common intraarticular T cell expansions in patients with reactive arthritis: identical α-chain junctional sequences and cytotoxicity toward HLA-B27. J Immunol 162:3830-3839
80. Shoenfeld Y, Vilner Y, Coates ARM, Rauch J, Shaul D, Pinkhas J (1986) Monoclonal antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol 66:255-261
81. Lindqvist KJ, Coleman RE, Osterland CK (1997) Autoantibodies in chronic pulmonary tuberculosis. J Chron Dis 22:717-725
82. Thorns CJ, Morris JA (1985) Common epitopes between mycobacteria and certain host tissue antigens. Clin Exp Immunol 61:323-328
83. Glynn P, Weedon D, Edwards J, Suckling AJ, Cuzner ML (1982) Humoral immunity in chronic relapsing experimental autoimmune encephalomyelitis. The major oligoclonal IgG bands are antibodies to mycobacteria. Neurol Sci 57:369-384
84. Van Eden W, Holoshitz J, Nevo A, Frenkel A, Klajman A, Cohen IR (1985) Arthritis induced by a T-lymphocyte clone that responds to mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci USA 82:5117-5120
85. Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF (1989) HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol 63:264-269
86. Pockley AG (2003) Heat shock proteins as regulators of the immune response. Lancet 362:469-476
87. Wick G, Perschinka, Millonig G (2001) Atherosclerosis as an autoimmune disease: an update. Trends Immunol 22:665-669
88. Zugel U, Schoel B, Yamamoto S, Hengel H, Morein B, Kaufmann SH (1999) Crossrecognition by CD8 T cell receptor αβ cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology. Eur J Immunol 25:451-458
89. Hara I, Sato N, Miyake H, Muramaki M, Hikosaka S, Kamidono S (2004) Introduction of 65 kDa antigen of Mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy. Microbiol Immunol 48:289-295
90. de Boer LC, Steerenberg PA, van der Meijen APM et al (1992) Impaired immune response by Isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol 148:1577-1582